Publications by authors named "Lise Boussemart"

21Publications

Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017.

J Invest Dermatol 2020 Oct 10. Epub 2020 Oct 10.

EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France; PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France; Department of Dermatology, CHU Rennes, Rennes, France. Electronic address:

View Article and Find Full Text PDF
October 2020

Melanoma tumour vasculature heterogeneity: from mice models to human.

J Cancer Res Clin Oncol 2019 Mar 13;145(3):589-597. Epub 2018 Dec 13.

UMR Inserm 1066, CNRS 6021, Université d'Angers, CHU, IBS, IRIS, MINT, UNIV Angers, INSERM, CNRS, Université Bretagne Loire, IBS-CHU, 4, rue Larrey, 49933, Angers, France.

View Article and Find Full Text PDF
March 2019

Woman, mother, and scientist: Aiming to fulfill a career in research while maintaining a "good-enough" work-life balance.

Authors:
Lise Boussemart

Int J Womens Dermatol 2016 Sep 25;2(3):74-76. Epub 2016 Jul 25.

Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France.

View Article and Find Full Text PDF
September 2016

Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

J Invest Dermatol 2017 04;137(4):805-809

Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France; Division of Medicine, Université de Rennes 1, Rennes, France; CNRS UMR6290, GEO team, IGDR, Rennes, France. Electronic address:

View Article and Find Full Text PDF
April 2017

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

JAMA Dermatol 2016 Jan;152(1):45-51

Department of Dermatology, Cancer Campus, Gustave Roussy Institute, Villejuif, France5Institut National de la Santé et de la Recherche Médicale U 981, Cancer Campus, Gustave Roussy Institute, Grand Paris, France.

View Article and Find Full Text PDF
January 2016

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Nature 2014 Sep 27;513(7516):105-9. Epub 2014 Jul 27.

1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).

View Article and Find Full Text PDF
September 2014

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

Cancer Res 2014 Apr 12;74(8):2238-45. Epub 2014 Feb 12.

Authors' Affiliations: Novartis Institutes for Biomedical Research, Emeryville; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California; Dermatology Unit and INSERM U 981; Department of Medical Biology and Pathology; Laboratory and Biobank; INSERM U 981, Institut Gustave Roussy, Villejuif Paris-Sud; and Unité de Génétique, Papillomavirus et Cancer Humain, Institut Pasteur, Paris, France.

View Article and Find Full Text PDF
April 2014

Vemurafenib and radiosensitization.

JAMA Dermatol 2013 Jul;149(7):855-7

Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.

View Article and Find Full Text PDF
July 2013

BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm.

Nat Biotechnol 2006 Nov 5;24(11):1402-11. Epub 2006 Nov 5.

Department of Gene and Cell Medicine, Black Family Stem Cell Institute, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA.

View Article and Find Full Text PDF
November 2006

L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus.

Proc Natl Acad Sci U S A 2004 Sep 15;101(39):14067-72. Epub 2004 Sep 15.

Microbiology and Immunology Department, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA.

View Article and Find Full Text PDF
September 2004